Effect of Allulose on Diet-induced Thermogenesis
Launched by TORONTO METROPOLITAN UNIVERSITY · Jul 17, 2024
Trial Information
Current as of July 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how a sweetener called allulose affects how our bodies burn calories from food, manage blood sugar levels, and how hungry we feel after eating. Researchers are particularly interested in how different amounts of allulose might influence these factors in healthy adults.
To participate in this study, you need to be between 18 and 45 years old, a non-smoker, and have a healthy body weight (a body mass index or BMI between 20 and 24.9). If you have certain health conditions, like diabetes or gastrointestinal issues, or if you've recently had major health events, you may not be eligible. If you join the study, you can expect to take part in tests that measure how your body responds to allulose, while being monitored in a safe environment. This trial is currently looking for participants, so if you're interested, it could be a great opportunity to contribute to understanding how this sweetener works in our bodies!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants (18 - 45 years) who are considered healthy, are non-smokers, and have a body mass index (BMI) between 20 and 24.9 kg/m2 \[World Health Organization classification of normal weight BMI\].
- Exclusion Criteria:
- • Participants who have a fasting plasma glucose \> 5.5 mmol/L indicative of impaired fasting glucose, previously diagnosed diabetes, known or uncertain pregnancy status at the screening visit, gastrointestinal disease, liver or kidney disease, have undergone a major medical or surgical event within the past 6 months, were or are on a diet, skip breakfast, smoke or have taken medication which would be a potential confounder with effects on metabolic and intake regulation.
- • Those unable to complete the testing protocols or are intolerant or allergic to test-day ingredients.
About Toronto Metropolitan University
Toronto Metropolitan University (TMU) is a leading urban institution dedicated to fostering innovative research and academic excellence. As a clinical trial sponsor, TMU leverages its interdisciplinary expertise and cutting-edge facilities to conduct impactful research that addresses pressing health challenges. Through collaboration with healthcare professionals, industry partners, and community stakeholders, TMU aims to translate scientific discoveries into practical solutions, enhancing patient care and advancing public health. Committed to ethical standards and rigorous methodologies, TMU ensures the integrity and reliability of its clinical trials, contributing to the advancement of medical knowledge and practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Nick Bellissimo
Principal Investigator
Toronto Metropolitan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported